JBIO vs KRYS vs REGN vs ABBV vs BEAM vs KO

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 14. 8x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Jade Biosciences, Inc. (JBIO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 14. 8x versus AbbVie Inc. at 96. 1x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2. 08x versus The Coca-Cola Company's 2. 26x.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +391. 1%, compared to -97. 8% for Jade Biosciences, Inc. (JBIO). Over 10 years, the gap is even starker: KRYS returned +28. 9% versus JBIO's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Beam Therapeutics Inc. 's 2. 18β — meaning BEAM is approximately -1190% more volatile than KO relative to the S&P 500. On balance sheet safety, Jade Biosciences, Inc. (JBIO) carries a lower debt/equity ratio of 0% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — KRYS leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2. 08x versus The Coca-Cola Company's 2. 26x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 13. 2x forward P/E versus 41. 0x for Krystal Biotech, Inc. — 27. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JBIO: 188. 1% to $44. 20.

In this comparison, ABBV (2.

9% yield), KO (2. 5% yield), REGN (0. 6% yield) pay a dividend. JBIO, KRYS, BEAM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, BEAM: +54. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (JBIO (Healthcare) and KRYS (Healthcare) and REGN (Healthcare) and ABBV (Healthcare) and BEAM (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: JBIO is a small-cap quality compounder stock; KRYS is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; ABBV is a large-cap quality compounder stock; BEAM is a small-cap high-growth stock; KO is a large-cap quality compounder stock. REGN, ABBV, KO pay a dividend while JBIO, KRYS, BEAM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.